Cargando…

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF(TM) 1

Inhibition of the epithelial sodium channel (ENaC) represents an important, mutation-agnostic therapeutic approach to restore airway surface liquid in patients with cystic fibrosis (CF). A phase II trial of the ENaC inhibitor BI 1265162, inhaled via the Respimat® Soft Mist™ inhaler, in patients aged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss, Christopher H., Jain, Raksha, Seibold, Wolfgang, Picard, Anne-Caroline, Hsu, Ming-Chi, Gupta, Abhya, Fajac, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Study Protocols
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720689/ https://www.ncbi.nlm.nih.gov/pubmed/33313307 http://dx.doi.org/10.1183/23120541.00395-2020

Ejemplares similares

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
por: Goss, Christopher H., et al.
Publicado: (2022)

Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
por: Nickolaus, Peter, et al.
Publicado: (2020)

First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
por: Mackie, Alison, et al.
Publicado: (2021)

RespiCell(TM): An Innovative Dissolution Apparatus for Inhaled Products
por: Sonvico, Fabio, et al.
Publicado: (2021)

Improving the care of patients with cystic fibrosis (CF)
por: Khan, Ahsan Aftab, et al.
Publicado: (2017)

Evaluation of tests to predict metallo-β-lactamase in cystic fibrosis (CF) and non-(CF) Pseudomonas
por: Perez, Leandro Reus Rodrigues, et al.
Publicado: (2014)

STAPHYLOCOCCUS AUREUS ENTEROTOXINS IN PEOPLE WITH CYSTIC FIBROSIS (CF)
por: Wen, Hongjie, et al.
Publicado: (2020)

Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era
por: Jain, Raksha, et al.
Publicado: (2021)

Development and validation of the Cystic Fibrosis Decisional Balance for Physical Activity scale (CF-DB-PA)
por: Filleul, Valentine, et al.
Publicado: (2021)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
por: Fajac, Isabelle, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

68 Respiratory viral detection in children with cystic fibrosis (CF)
por: Tješić-Drinković, I., et al.
Publicado: (2015)

Disease-specific clinical trials networks: the example of cystic fibrosis
por: De Boeck, Kris, et al.
Publicado: (2016)

Rehabilitation Programs for Cystic Fibrosis – View from a CF Center
por: Griese, M, et al.
Publicado: (2010)

Paraquat ingestion in an adult with cystic fibrosis (CF): Diagnostic and management dilemmas
por: Evans, Ieuan E. S., et al.
Publicado: (2023)

Motion analysis of suturing technique with Leap Motion Controller(TM). Proof-of-concept
por: Tsuyuki, Shota, et al.
Publicado: (2022)

Two cases of non-cystic fibrosis (CF) bronchiectasis with allergic bronchopulmonary aspergillosis
por: De, Hriday, et al.
Publicado: (2016)

1481. Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients
por: Edwards, Brett, et al.
Publicado: (2018)

Oral Hygiene and Periodontal Treatment Needs in Adult Patients with Cystic Fibrosis (CF)
por: Hildebrandt, Tomasz, et al.
Publicado: (2022)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology
por: Barone, Simona, et al.
Publicado: (2022)

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf
por: Chalmers, James D., et al.
Publicado: (2023)

TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease
por: Steinke, Eva, et al.
Publicado: (2023)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Improving health literacy of antibiotic use in people with cystic fibrosis (CF)—comparison of the readability of patient information leaflets (PILs) from the EU, USA and UK of 23 CF-related antibiotics used in the treatment of CF respiratory infections
por: Tang, Ka Wah Kelly, et al.
Publicado: (2023)

Draft Genome Sequence of Triclosan-Resistant Cystic Fibrosis Isolate Achromobacter xylosoxidans CF304
por: Jeukens, Julie, et al.
Publicado: (2015)

1257. Assessing Risk Factors for an Outbreak of Burkholderia cenocepacia in Non-cystic Fibrosis (CF) Patients
por: Hill-Ricciuti, Alexandra, et al.
Publicado: (2018)

The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
por: Ronchetti, Katherine, et al.
Publicado: (2018)

Theoretical insight into OH- and Cl-initiated oxidation of CF(3)OCH(CF(3))(2) and CF(3)OCF(2)CF(2)H & fate of CF(3)OC(X•)(CF(3))(2) and CF(3)OCF(2)CF(2)X• radicals (X=O, O(2))
por: Bai, Feng-Yang, et al.
Publicado: (2017)

Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry
por: Yiallouros, Panayiotis K., et al.
Publicado: (2021)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections
por: Heirali, Alya, et al.
Publicado: (2016)

Connexin 37 and Connexin 43 genotypes in correlation to cytokines in induced sputum and blood in cystic fibrosis (CF)
por: Ludwig, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nnv81k4uis4pp8bl0kg28vdtt5